Young-onset Parkinson's disease (YOPD) is a relevant condition whose neurobiology is questioned if different from those of typical late-onset Parkinson's disease (LOPD). Here, we explored whether the clinical-biochemical profile of Parkinson's disease (PD) could be affected by the age-of-onset (AO), as a possible result of a distinct neurodegenerative process. A panel of fluid biomarkers (CSF lactate, 42-amyloid-β peptide, total and 181-phosphorylated tau; serum uric acid) and the standard scores for motor and nonmotor signs were assessed in 76 idiopathic PD patients (genetic cases excluded; YOPD, AO ≤ 50, n = 44; LOPD, AO > 50, n = 32) and 75 sex/age-matched controls, adjusting the models for the main confounding factors. In PD, AO directly correlated to either CSF lactate and tau proteins or the nonmotor symptoms scale score. Specifically, a younger AO was associated with lower levels of biomarkers and minor burden of nonmotor symptoms. Our findings indicate that clinical-biochemical features of idiopathic PD may vary depending on the AO, accounting for different profiles in YOPD and LOPD whose recognition is fundamental for further pathophysiological implications and clinical applications.

中文翻译：

---

年轻发作和迟发性帕金森病表现出不同的体液生物标志物和临床特征。

年轻型帕金森病 (YOPD) 是一种相关疾病，其神经生物学是否与典型晚发性帕金森病 (LOPD) 的神经生物学不同。在这里，我们探讨了帕金森病 (PD) 的临床生化特征是否会受到发病年龄 (AO) 的影响，这可能是一种明显的神经退行性过程的结果。在 76 名特发性 PD 患者（排除遗传病例；YOPD、 AO ≤ 50，n = 44；LOPD，AO > 50，n = 32）和 75 个性别/年龄匹配的对照，调整主要混杂因素的模型。在 PD 中，AO 与 CSF 乳酸和 tau 蛋白或非运动症状量表评分直接相关。具体而言，年轻的 AO 与较低水平的生物标志物和轻微的非运动症状负担相关。我们的研究结果表明，特发性 PD 的临床生化特征可能因 AO 而异，说明 YOPD 和 LOPD 的不同特征，其识别是进一步病理生理学意义和临床应用的基础。